Neurogenic fever: Difference between revisions
From IDWiki
(Created page with "==Background== ===Pathophysiology=== * Thought to relate to damage to the hypothalamus, increasing levels of prostaglandin E * May be related to release of prostaglandin E dur...") |
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
||
| Line 8: | Line 8: | ||
* Also occurs in 4 to 37% of patients with traumatic brain injury |
* Also occurs in 4 to 37% of patients with traumatic brain injury |
||
==Clinical |
==Clinical Manifestations== |
||
* Occurs more commonly in patients with subarachnoid hemorrhage, intraventricular hemorrhage, or brain tumour |
* Occurs more commonly in patients with subarachnoid hemorrhage, intraventricular hemorrhage, or brain tumour |
||
** In TBI, diffuse axonal injury and frontal lobe damage appear to be specific risk factors |
** In TBI, diffuse axonal injury and frontal lobe damage appear to be specific risk factors |
||
Latest revision as of 23:25, 14 July 2020
Background
Pathophysiology
- Thought to relate to damage to the hypothalamus, increasing levels of prostaglandin E
- May be related to release of prostaglandin E during initial trauma, given that it is more commonly seen soon after admission
Epidemiology
- Unidentified focus of fever occurs in up to 26% of patients with subarachnoid hemorrhage
- Also occurs in 4 to 37% of patients with traumatic brain injury
Clinical Manifestations
- Occurs more commonly in patients with subarachnoid hemorrhage, intraventricular hemorrhage, or brain tumour
- In TBI, diffuse axonal injury and frontal lobe damage appear to be specific risk factors
- More commonly seen within 72 hours of admission
- Typically shorter duration (mean 1.4 days versus 4.2 for infectious fevers)
Further Reading
- Neurogenic Fever: Review of Pathophysiology, Evaluation, and Management. J Intensive Care Med. 2017;32(2):124-129. doi: 10.1177/0885066615625194
